Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MGCD0103 in acute myelogenous leukemia/high-risk myelodysplastic syndromes
2006-005872-42Phase 2Terminated
- Sponsor
- Pharmion
- Start
- Jan 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of mocetinostat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Pharmion. Primary endpoint: Overall response rate (CR + CRi + PR). Started Jan 2007; status: terminated.
02
Drugs
mocetinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2006-005872-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005872-42.